Harmony's Next CEO Says Its $1 Billion-Plus Cash Won't Go On One Deal

Peter Anastasiou, who becomes CEO January 1, 2027, plans multiple deals and a search beyond rare neurological disease.

Share
Harmony's Next CEO Says Its $1 Billion-Plus Cash Won't Go On One Deal

Harmony Biosciences, the neuroscience drugmaker behind the narcolepsy pill Wakix, plans to split its cash among several deals, incoming CEO Peter Anastasiou said on its third-quarter call Wednesday. The company holds over $1 billion in cash, equivalents and investments, against $150 million in debt.

Several deals, not one

Anastasiou, the company's chief operating officer, said Harmony has "both the capacity and the conviction to execute on meaningful transactions." He succeeds Dr. Jeffrey Dayno on January 1, 2027.

"You should not expect that we will allocate all of that capital on one transaction," he told analysts. Instead, he said, Harmony will likely do multiple deals that together "can be transformative for harmony."

He described two targets. One is assets that add revenue in the 2028 to 2032 window to support the company's self-funded model, with priority on drugs in Phase 3, in registration or on the market. The other is innovative pipeline assets that build long-term value, as the company says its orexin candidate BP205 can. Both M&A and licensing are on the table.

An analyst at Piper Sandler asked about the "broader aperture" within central nervous system disease. Anastasiou said sleep and epilepsy remain priorities, and that orexin-linked areas such as cognition, attention, mood and fatigue will guide where Harmony looks for deals.

Leaning on one drug

Harmony is a neuroscience company focused on rare neurological diseases. Its only marketed product, Wakix, is a once-daily tablet for excessive daytime sleepiness and cataplexy in narcolepsy. Wakix brought in $269 million in the third quarter, and management reiterated full-year guidance of $1 billion to $1.04 billion.

Company net revenue was $269 million, against $239 million a year earlier. Net income was $48 million, or 81 cents per diluted share. Average Wakix patients reached about 9,350, up 400 in the quarter. Chief Commercial Officer Adam Zaeske said about 170,000 people in the U.S. have narcolepsy, fewer than 50% are diagnosed, and brand penetration is about 20%.

Shares traded at $33.71 in Wednesday trading, down about 9% from the prior close.

Patents, BP205 and the next dates

Anastasiou said Harmony has settled with six of seven generic filers and expects Wakix exclusivity to March 2030. A judge scheduled a preliminary injunction hearing for January 26, 2027, with a decision expected by February 14, 2027, when the 30-month stay expires.

BP205 is the internal answer for later growth. Phase 1 multiple-dose data showed a profile consistent with earlier results, and data from a sleep-deprived volunteer study are expected in the first quarter of 2027. Phase 2 studies across several CNS indications are planned to start by mid-2027.

Anastasiou said the deals together could reshape Harmony, and the January 26 injunction hearing is the next dated test of the patent protection behind Wakix.

Sources

More on Harmony Biosciences

All Harmony Biosciences (HRMY) coverage →